Michael Lauw
Vice President, Clinical Development, Lineage Cell Therapeutics, Inc.

Abstract

Clinical Product Development - The Winding Road

Lineage Cell Therapeutics continues to progress the development of OPC1, a cell transplant approach designed to replace or support cells that are absent or dysfunctional due to traumatic injury, with a goal to help improve the quality of life and restore or augment functional activity in persons suffering from traumatic spinal cord injuries.  Moving from the bench to an approved therapy is costly.  Cell therapies are complex adding to the challenges finances play in their development. This presentation will give a history of OPC1, what we have learned, what progress we have made, and discuss what is needed to make this a viable, commercially available treatment.

 

Bio
Michael Lauw currently serves as Vice President, Clinical Development at Lineage Cell Therapeutics, Inc. (NYSE American: LCTX), where he leads the development of OPC1, a cell therapy for treatment of functional impairment of spinal cord injury (SCI). Michael has over 25 years of industry experience leading clinical product development, medical affairs, and study operations teams. He has worked in a wide variety of therapeutic areas (extensively in gastroenterology, CNS, cardiovascular/hematology, endocrinology, and areas of rare disease), utilizing gene therapy and small/large molecule approaches leading to approved products in gout, multiple sclerosis, and inflammatory bowel diseases. Michael’s clinical background is in social work, fulfilling his first internship at the VA San Diego Healthcare System SCI and Associated Disorders Rehabilitation Services Unit.